Arsanis raises $20m to finance anti-infection MAb 'cocktail'
This article was originally published in Scrip
Executive Summary
Austrian biotech Arsanis has raised $20m in a series B round, which it plans to use to progress its lead monoclonal antibody program against Staphylococcus aureus, ASN-100.